Free Trial

10 Best Penny Stocks to Buy Now - 2 of 10

 
 

CytomX Therapeutics (NASDAQ:CTMX)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Moderate Buy
Rating Score
2.5
Ratings Breakdown
3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$5.77 (523.9% Upside)

About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingNeutral
9/13/2024HC WainwrightReiterated RatingNeutral
8/22/2024HC WainwrightReiterated RatingNeutral
6/27/2024HC WainwrightReiterated RatingNeutral
5/28/2024Piper SandlerUpgradeNeutral ➝ Overweight$2.25 ➝ $3.50
5/9/2024BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$3.25 ➝ $3.59
5/9/2024HC WainwrightReiterated RatingNeutral
5/9/2024WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $8.00
5/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$2.50 ➝ $8.00
5/1/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$3.25
 

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.